| Andrea M Corse, MD | |
|
600 N Wolfe St, Baltimore, MD 21287-0005 | |
| (410) 955-9441 | |
| Not Available |
| Full Name | Andrea M Corse |
|---|---|
| Gender | Female |
| Speciality | Neurology |
| Experience | 37 Years |
| Location | 600 N Wolfe St, Baltimore, Maryland |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114974268 | NPI | - | NPPES |
| 755871600 | Medicaid | MD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084N0400X | Psychiatry & Neurology - Neurology | D42763 (Maryland) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Johns Hopkins Hospital, The | Baltimore, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Johns Hopkins University | 8921903147 | 2692 |
News Archive
Three studies conducted as part of Wayne State University's Systems Biology of Epilepsy Project (SBEP) could result in new types of treatment for the disease and, as a bonus, for behavioral disorders as well.
Scientists from Queen Mary University of London and UCL (University College London) have identified what they believe could be a cause of pre-term premature rupture of the fetal membrane (PPROM), which accounts for 40 per cent of pre-term births, and is the main reason for infant death world-wide.
Howard Florey Institute have opened up new treatment possibilities for Huntington's disease by proving a scientific theory incorrect.
AbbVie released preliminary results from an ongoing Phase I study with ABT-414, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody drug conjugate, in combination with temozolomide, which showed four objective responses, including one complete response, in patients with recurrent or unresectable glioblastoma multiforme.
› Verified 3 days ago
| Entity Name | Johns Hopkins University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922008549 PECOS PAC ID: 8921903147 Enrollment ID: O20031215000719 |
News Archive
Three studies conducted as part of Wayne State University's Systems Biology of Epilepsy Project (SBEP) could result in new types of treatment for the disease and, as a bonus, for behavioral disorders as well.
Scientists from Queen Mary University of London and UCL (University College London) have identified what they believe could be a cause of pre-term premature rupture of the fetal membrane (PPROM), which accounts for 40 per cent of pre-term births, and is the main reason for infant death world-wide.
Howard Florey Institute have opened up new treatment possibilities for Huntington's disease by proving a scientific theory incorrect.
AbbVie released preliminary results from an ongoing Phase I study with ABT-414, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody drug conjugate, in combination with temozolomide, which showed four objective responses, including one complete response, in patients with recurrent or unresectable glioblastoma multiforme.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Andrea M Corse, MD Po Box 64227, Baltimore, MD 21264-4227 Ph: () - | Andrea M Corse, MD 600 N Wolfe St, Baltimore, MD 21287-0005 Ph: (410) 955-9441 |
News Archive
Three studies conducted as part of Wayne State University's Systems Biology of Epilepsy Project (SBEP) could result in new types of treatment for the disease and, as a bonus, for behavioral disorders as well.
Scientists from Queen Mary University of London and UCL (University College London) have identified what they believe could be a cause of pre-term premature rupture of the fetal membrane (PPROM), which accounts for 40 per cent of pre-term births, and is the main reason for infant death world-wide.
Howard Florey Institute have opened up new treatment possibilities for Huntington's disease by proving a scientific theory incorrect.
AbbVie released preliminary results from an ongoing Phase I study with ABT-414, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody drug conjugate, in combination with temozolomide, which showed four objective responses, including one complete response, in patients with recurrent or unresectable glioblastoma multiforme.
› Verified 3 days ago
Dr. Michelle Schnabel Horner, D.O. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 5500 E Lombard St, Baltimore, MD 21224 Phone: 410-550-0091 | |
Dr. Priscilla Waldo Sheldon, M.D., PH.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1001 W Pratt St, Baltimore, MD 21223 Phone: 410-962-7180 Fax: 410-962-7194 | |
Haopeng Zheng, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 345 Saint Paul Pl, Baltimore, MD 21202 Phone: 410-332-9000 | |
Ms. Sarah Catherine Collica, Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 600 North Wolfe St, Baltimore, MD 21287 Phone: 410-955-5000 | |
Abdullah Bin Zahid, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 600 N Wolfe Street Phipps 455, Baltimore, MD 21264 Phone: 410-933-6423 | |
Chelsea Cosner, Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 701 W Pratt St Rm 474, Baltimore, MD 21201 Phone: 410-328-6325 | |
Michael Andre Torres, M.D. Psychiatry & Neurology Medicare: May Accept Medicare Assignments Practice Location: 600 Wyndhurst Ave, Suite 160, Baltimore, MD 21210 Phone: 410-617-0605 Fax: 443-773-1406 |